Pfizer’s Prevnar 20 May Have Edge Over Merck’s Pneumococcal Vaccine, ACIP Suggests

 
• By Brenda Sandburg

CDC advisory committee work group concludes benefits of Merck’s PVC15 in those 65 and older is small while benefits of Pfizer’s PVC20 in those 50 and older is large and in those 65 and older is moderate to large.

Pneumococcal vaccine
CDC advisory committee asseses Pfizer and Merck pneumococcal vaccines • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers